The most common anti-PD-1-related AEs (grade superior or equal to 3) for HL and DLBCL patients were blood disorders (78.1% and 59.1%, respectively), hepatic disorders (34.2% and 25.0%, respectively) and kidney disorders (21.9% and 18.2%, respectively) (Table 2). Here, PDCD1 is linked to kidney disorder.